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ABSTRACT: Parkinson’s disease biomarkers are
needed to increase diagnostic accuracy, to objectively
monitor disease progression and to assess therapeutic
efficacy as well as target engagement when evaluating
novel drug and therapeutic strategies. This article sum-
marizes perianalytical considerations for biomarker
studies (based on immunoassays) in Parkinson’s dis-
ease, with emphasis on quantifying total a-synuclein
protein in biological fluids. Current knowledge and pit-
falls are discussed, and selected perianalytical variables
are presented systematically, including different temper-
ature of sample collection and types of collection tubes,
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gradient sampling, the addition of detergent, aliquot vol-
ume, the freezing time, and the different thawing meth-
ods. We also discuss analytical confounders. We
identify gaps in the knowledge and delineate specific
areas that require further investigation, such as the
need to identify posttranslational modifications of a-
synuclein and antibody-independent reference methods
for quantification, as well as the analysis of potential
confounders, such as comorbidities, medication, and
phenotypes of Parkinson’s disease in larger cohorts.
This review could be used as a guideline for future Par-
kinson’s disease biomarker studies and will require reg-
ular updating as more information arises in this growing
field, including new technical developments as they
become available. In addition to reviewing best practi-
ces, we also identify the current technical limitations
and gaps in the knowledge that should be addressed to
enable accurate and quantitative assessment of a-
synuclein levels in the clinical setting. VC 2017 The
Authors. Movement Disorders published by Wiley Peri-
odicals, Inc. on behalf of International Parkinson and
Movement Disorder Society.
Key Words: Biomarker; a-synuclein; cerebrospinal
fluid; standard operating procedures; Parkinson’s
disease; diagnostics
Parkinson’s disease (PD) is characterized by the pres-
ence of cytoplasmic a-synuclein (aSyn) aggregates, pro-
gressive neuronal impairment, and eventually neuronal
death. Lost neurons generally cannot be replaced. There-
fore, agents aimed at inhibiting neurodegenerative pro-
cesses are likely to be most effective if administered at the
earliest stages of the disease process. However, clinical or
pathological manifestations of the disease in early disease
stages are often difficult to detect, and the definite diagno-
sis is made postmortem through neuropathology.1 Fur-
thermore, it can be difficult to distinguish PD from
atypical parkinsonian disorders including multiple system
atrophy, progressive supranuclear palsy, and corticobasal
degeneration, and dementia with Lewy bodies. Misdiag-
noses occur in a substantial proportion of patients, partic-
ularly in general neurology practice, whereas movement
disorder specialists achieve up to 90% accuracy.2 In fact,
one study led by a fellowship-trained movement disorder
specialist found an inaccurate diagnosis in 7 of 15 subjects
diagnosed with PD within 5 years.3
Also, different phenotypes of PD that have emerged
from cluster analyses warrant careful evaluation and
subtype-specific biomarker considerations.4,5 For these
reasons, biomarkers that specifically reflect onset and pro-
gression of pathology may have a profound impact on
diagnosis, detection, assessment of treatment efficacy,
and patient stratification in future clinical trials. Accord-
ing to the National Institute of Health Biomarkers Defini-
tions Working Group, a biomarker is a “characteristic
that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention.”6
PD biomarkers include structural and/or functional
imaging, functional tests, and, most recently, tissue anal-
ysis and assays in biological fluids. An ideal biomarker
reflects the underlying pathophysiological process and is
optimally proximal to the molecular disease onset and
progression. Cerebrospinal fluid (CSF), primarily pro-
duced by the choroid plexus within the ventricles of the
central nervous system (CNS), is a promising biological
fluid to study neurodegenerative disorders and can be
easily accessed by routine lumbar punctures (LPs). It is
known that 80% of CSF composition (ie, proteins)
derives from the filtration of peripheral blood, whereas
20% derives from CNS cells.7
A triplet of CSF biomarkers for Alzheimer’s disease
(AD), total and phosphorylated tau, which may reflect
AD-type axonal degeneration, and b-amyloid (Ab) 1-42,
which reflects senile plaque pathology, have already
been established for early (predementia) detection of
AD.8 The biomarker field in PD can leverage the experi-
ences and standardization efforts on preanalytical
aspects of CSF biomarkers from the AD field,9,10 includ-
ing regulatory aspects of biomarker research, encom-
passing fluid and imaging biomarkers to support clinical
trials.11 The AD markers have been included in Euro-
pean Medicines Agency guidance documents12 and were
described in a letter of support of the Food and Drug
Administration qualification process.13 No identical
efforts have yet been initiated for PD biomarkers.
The identification of aSyn as the main component of
Lewy bodies in 199714,15 combined with evidence of a
disease-causing gene dosage effect15,16 and the detection
of aSyn in CSF led to the quantification of CSF aSyn as a
candidate biomarker for the early diagnosis of PD.17-21
The PD field is now involved in a systematic exploration
of posttranslational modifications of aSyn22,23 and other
surrogate biomarkers. In parallel, efforts are under way to
develop and analytically validate assays of emerging bio-
markers (including phosphorylated aSyn) and the creation
of certified reference materials and methods (eg, based on
mass spectrometry) that could support clinical trials of
putative disease-modified therapies of PD, as well as aid in
obtaining regulatory approval for the biomarkers.24
The quantification of total aSyn in the CSF with
sandwich-type enzyme-linked immunosorbent assays
(ELISAs) or other technology platforms has been
described by several groups with varying results (as
reviewed in reference 17). Based on data from single-
and multicenter studies,19,21,25-27 a consensus is now
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emerging that PD pathogenesis is associated with a
10-20% reduction in total aSyn in CSF. Whether this
reduction reflects Lewy body formation needs to be
confirmed. Although aSyn expression has been identi-
fied in several extracerebral tissues including erythro-
cytes, there are data suggesting that CSF aSyn
predominantly derives from neurons of the CNS.18,28
However, it is still unclear if the CSF derived from the
plexus already contains aSyn from the peripheral
blood.29 Blood-derived aSyn might be important if the
blood-brain barrier is compromised, especially in light
of experimental data demonstrating that peripherally
injected aSyn readily reaches the brain in mice.29
Reliance on LPs and CSF as the major matrix for
biomarker assay development in biological fluids is
not optimal. The distribution of PD-linked aSyn
pathology points toward a systemic disease with early
involvement of the peripheral nervous system and
organs.30 Therefore, there is a high possibility of
detecting a peripheral marker in accessible biological
fluids throughout less invasive procedures (at least
compared with CSF) that is still proximal to the dis-
ease process.
An increasing number of studies have been explor-
ing peripheral body fluids and biopsy sites as potential
sources for aSyn biomarker analysis. In fact, after
aSyn pathology was found in submandibular salivary
glands31 (and is now being investigated as a biopsy-
based biomarker for PD in vivo32), a recent study
detected aSyn in the saliva as a possible biomarker.33
ASyn has already been shown to be quantifiable in
peripheral blood compartments34,35 where red blood
cells with high aSyn load are a large contributor.28,36
Not much is known about aSyn isoforms and/or frag-
ments in peripheral biospecimens. However, to date,
the findings on blood total aSyn as a diagnostic bio-
marker have been inconsistent, which may be because
of different sample processing, variations in standardi-
zation of methods and assays, and other confounding
factors (eg, erythrocyte lysis).20,37-40 As such, the role
of aSyn in peripheral fluids in the pathophysiology of
PD is still unclear. Some of these blood-processing
issues can be avoided by the analysis of stabilized
RNA in blood collected via PAX gene tubes (PreAna-
lytix) and by focusing on aSyn encoding gene (SNCA)
transcripts instead of proteins.26
One of the main obstacles preventing the use of CSF
and blood-based aSyn biomarkers in routine diagnosis
or individual patient management is interindividual vari-
ability and interstudy variability of aSyn levels, reaching,
in some cases, coefficient variations of 20%-35% for
interassay and interlaboratory measurements.25,27,41
Several preanalytical, analytical, and assay-related issues
need to be addressed before global implementation of
reliable biomarkers for diagnosis, prognosis, and moni-
toring of novel therapeutics in PD can occur.
The major impetus for this article is to summarize
the current state of development of potential aSyn pro-
tein biomarker assays for PD, to critically discuss
them, and to elucidate the gaps in knowledge that still
need to be addressed. We will update this article on a
regular basis as is done in other initiatives (Alz-
heimer’s disease neuroimaging initiative and European
Union initiatives).42 Our goal is to facilitate biomarker
research and share information so that all investi-
gators have access to pertinent information regarding
how to best set up, validate, and ultimately interpret
various assays/results. This article will refer to some
original publications (cited in parentheses and pro-
vided in the accompanying reference list), as well as
unpublished data. The latter have been generated
through a consortium of scientists and companies that
make up the Michael J. Fox Foundation’s (MJFF)
Investigating Synuclein Consortium (ISC). The ISC is
composed of 30 academic and industry investigators
around the world whose ongoing projects around
aSyn assay development, optimization, and validation
are supported by the MJFF. These investigators have
agreed to share data, critical information, tools, and
reagents in real time as they all work toward the same
goal of understanding PD-relevant aSyn species and
developing biomarker assays to measure them.
The ISC, is composed of, in part, the MJFF aSyn
Assay Standardization Linked Efforts to Accelerate
Parkinson’s Solutions (LEAPS) team. The goal of this
initiative is to initially compare 3 already commer-
cially available aSyn assays, as well as newly devel-
oped assays and a newly developed mass spectrometry
assay in a round robin comparison study using the
same set of 50 CSF, saliva, and whole-blood samples.
The LEAPS team is also charged with assessing a vari-
ety of currently available aSyn protein standards and
examining the effect of preanalytical variables on
assay performance. A similar study on phosphorylated
aSyn and oligomeric aSyn is also in progress.
The content of the following section is related to
total aSyn measurements unless otherwise indicated
(eg, as posttranslationally modified aSyn).
This article builds on previous reviews addressing
mainly preanalytical variables43 and recommendations
for standardization.44-46 Our recommendations are
summarized in Table 1. We include recommendations
on CSF and blood biomarkers, although for the latter
matrix, systematic data are currently lacking.
Standardization and Confounding Factors
Biomarker standardization efforts include preanalyt-
ical considerations with potential confounding factors,
such as nutrition and medication, sample collection
and sample processing, storage and the quantification
platforms, antibodies, and reference material as well
as interpretation. The outcome of the standardization
a- S Y N U C L E I N B I O M A R K E R S T U D I E S I N P D
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TABLE 1. Suggested standard operating procedures (modified from references 17 and 44) for aSyn studies and evidence
level
CSF aSyn studies Rationale and evidence Blood aSyn studies Rationale and evidence
Preanalytical considerations
Perform lumbar puncture in the
morning with fasting patient
Avoid change of composition by
nutrients (evidence level a).
Same as in CSF Avoid change of composition by
nutrients. (evidence level a)
Document medication and
comorbidities for further
correlation
Enable to investigate influence of
pharmacotherapy and concomitant
diseases. Correlation between the
aSyn levels in treated PD subjects
with at least the levodopa
equivalent daily dosage (eg,
according to Tomlinson76 and also
suggest correlation with substance
classes (such as dopamine
agonists, MAO-B inhibitors)
(evidence level a).
Same as in CSF Same as CSF
Sampling variables
Use atraumatic needles Decrease of side effects (especially
post-lumbar puncture headache
and artificial blood
contamination).77 Up to 22-gauge
needles allow the regular
collection of CSF, whereas
smaller-diameter needles (24
gauge) would require syringe
sucking to enable the collection of
10-12mL in a realistic time frame,
which can also cause artifacts
(through cell lysis, material of the
syringe) (evidence level c).
Venous puncture. If manually
sucking tubes are used, care
should be taken to avoid a
significantly forced blood draw
(to decrease hemolysis).
Vacuum systems might be
preferred as the vacuum is
defined
Avoid hemolysis through incorrect
handling of blood tubes
(evidence level a)
Collect with polypropylene or
siliconized tubes
Decrease aSyn adsorption (Fig. 2;
evidence level b).
Collect with polypropylene or
siliconized tubes
Same as CSF
Discard first 5 drops of CSF Remove artificially blood
contamination through needle
insertion (evidence level a).
Fill blood tubes to the maximum
(evidence level b)
No data
Collect the first 2mL separately
for cell count, routine analysis.
A standardized collection
volume should be used,
preferably 10-15mL of lumbar
CSF
Because of the rostrocaudal gradient,
the volume taken should remain
constant. If more CSF is taken, for
example, for NPH patients, the
first 10-15mL should be
processed in accordance
(evidence level b).
No data No data
Sample processing
Samples should be processed
quickly to avoid delay until
freezing (evidence level b)
Samples need to be screened for
blood contamination (by
counting red blood cells as
soon as possible) and/or
quantification of hemoglobin
(can be done in already frozen
samples)
Hemoglobin contamination can
influence biomarker
measurements. Samples with
blood contamination (>50/mL) or
hemoglobin level> 200 ng/mL
should be excluded (evidence
level c).
Fast processing to avoid
hemolysis. Quantification of
hemoglobin possible
Same as CSF
Centrifuge samples before
freezing
Cells (physiologically occurring or
artificially through blood contami-
nation) should be removed by
centrifugation (evidence level c).
Centrifuge samples before
freezing to obtain serum and
plasma
Study the tube vendors
recommendation on the centri-
fugation (evidence level c)
Volume of aliquots To prevent gradient effect, take off
supernatant and mix gently in a
new (siliconized/polypropylene
tube) and aliquot in ONE aliquot
size (eg, 0.25ml), avoid “dead
volume” (Fig. 5; evidence level a).
Careful handling of supernatant is
important to avoid
contamination with blood
No data
(Continued)
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studies is dependent, in part, on the assay design (eg,
selected antibody combinations, buffers) and can
explain some of the discrepant results between studies.
To assess a first selection of possible perianalytical
variables on aSyn measurements, we collected CSF
samples from subjects with normal-pressure hydro-
cephalus (NPH) and processed the samples as indi-
cated in the legends of Figures 1–6. The selected
perianalytical variables included different collection
temperatures and different collection tube materials,
gradient collection, the addition of detergent, aliquot
volume, time to freeze, and different thawing
methods.
Perianalytical Considerations for CSF aSyn
Perianalytical factors include all the steps before,
around, and after analysis, whereas preanalytical fac-
tors are possible confounders that may introduce vari-
ability before the actual analysis of a biomarker.
Perianalytical factors include in vivo biological factors
affecting the subject at the time of sample collection
(such as fasting or diurnal and seasonal variations).
Little is known about how biological factors (ie, on
genetic or neuropathological grounds) may influence
aSyn levels in biological fluids. The PD sample cohorts
analyzed to date have been too small to draw signifi-
cant conclusions.47
Other perianalytical confounding factors can occur
during sample handling and processing. Such in vitro
factors can greatly impact biochemical analysis; it
has been reported that approximately 40-60% of
observed laboratory errors are because of such preana-
lytical procedures.17 This is of particular concern for
PD biomarker analyses, because aSyn is highly abun-
dant in the peripheral blood and blood contamination
occurs in 14-20% of LP procedures.13,18,19
The following section summarizes the currently
known perianalytical variables affecting aSyn assay
performance. We recognize and leave open the possi-
bility of including additional variables as data become
available in the online version of this article, which
appears on the MJFF website (see below).
TABLE 1. Continued
CSF aSyn studies Rationale and evidence Blood aSyn studies Rationale and evidence
Process within 60 minutes
(optimally 30 minutes) after
lumbar puncture
To avoid changes of CSF, ex vivo
samples should be processed
quickly (Fig. 6; evidence level a).
Same as CSF
Storage and shipment of samples
Store all samples after
processing in 280 8C
Avoid needless freezing and
thawing cycles. Thaw samples
on ice before applied
Freezing and thawing have been
shown to decrease signal intensity
and increase oligomerization
(evidence level c). Allow 1 extra
freeze/thaw cycle.
Same as CSF
Shipment of samples Processed and frozen samples
should be shipped on dry ice
(evidence level c).
Same as CSF
Preanalytical sample handling
Thaw samples completely on ice Incomplete thawed samples could
impact results. Figure 6 (evidence
level a)
Same as CSF
Addition of blockers for
heterophilic antibodies can be
considered, esp. for blood
No extra benefit (evidence level a). Same as CSF
Analytical variables
Exclude samples with unknown
or high levels of hemoglobin
Hemoglobin can be retrospectively
quantified in frozen samples.
Samples with blood contamination
(>50/mL) or hemoglobin
level> 200 ng/mL should be
excluded (evidence level c).
Same as CSF
aRecommendation without robust multilaboratory investigation.
bOne investigation performed by one group, published or communicated, not independently validated.
cOne investigation (of our own group), not independently validated.
dRecommendation supported by 2 independent investigations.
eRecommendation supported by> 2 independent investigations.
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Medication
How pharmacotherapy and dopaminergic medica-
tion in PD influence CSF aSyn levels is not yet clear.
One study described the expression of dopamine re-
ceptors in the choroid plexus, where CSF is pro-
duced,48 which could influence the homeostasis of
CSF components, including aSyn.
Within the Parkinson Progression Marker Initiative
(PPMI; for more information: www.ppmi-info.org) of
MJFF longitudinal sample analysis, we analyzed
whether use of PD medications and the levodopa
equivalent daily dosages during a 12-month follow-up
period was associated with changes in CSF bio-
markers. We found that patients using dopamine ago-
nists (but not dopamine replacements) had lower
levels of aSyn than unmedicated patients. There was
no obvious relationship with changes in other CSF
biomarkers.49 Further analysis of this apparent associ-
ation using data from subsequent visits in the PPMI
study is required to understand the relevance of these
preliminary findings.
Diurnal Variation, Fasting
A clearance of metabolites from the brain interstitial
space into the CSF occurs during sleep.50 As such, a
circadian rhythm of CSF biomarker concentrations is
possible. Diurnal variation of biomarkers can be a
critical factor in the concentration of specific biochem-
ical compounds that are influenced by potential circa-
dian rhythms. In case of a circadian rhythm, the time
of day when the LP/blood draw is performed can be
of importance.51 Several AD studies have already
characterized the diurnal variation of CSF bio-
markers.52 For CSF aSyn, there does not appear to be
any diurnal fluctuation, although a potential gradient
and/or effect of high sampling volume appears to
affect aSyn levels.
Whether food/drink intake influences CSF bio-
markers and especially CSF aSyn levels is not known.
Very little is known about the influence of diurnal var-
iation/ fasting on aSyn levels in other biological fluids
(eg, saliva and blood matrices).
Sampling Variables for PD Biomarkers
Type of Needle for Lumbar Puncture
Although headache has been reported to occur less
in elderly subjects,53 postpuncture headache impacts
acceptance in patients and should be an important
consideration for biomarker studies.
Because aSyn is highly abundant in peripheral
blood, accidental blood contamination should be avo-
ided. To evaluate the effects of LP practice on acciden-
tal blood contamination, hemoglobin levels were
assessed in baseline LP samples of 671 subjects (early
PD and healthy controls) enrolled in the PPMI study.
Hemoglobin levels were compared in the CSF from
those subjects who underwent LP using atraumatic
needles (n5 535) versus sharp needles (n5 128; for
8 subjects the information was missing): CSF from
LPs with atraumatic needles compared with those
with traumatic needles showed significantly less hemo-
globin contamination (P50.014).
Volume (Including Gradient Effect)
After the production of CSF by filtration, CSF leaves
the ventricles beneath the cerebellum and permeates the
CNS, introducing blood-derived proteins to the CSF in
this fashion. Therefore, the composition of CSF taken
from the ventricles is different from the CSF tapped by
LP around the lumbar spine. The lumbar CSF contains
more blood-derived proteins (eg, albumin) than the ven-
tricular CSF. On the other hand, most brain-derived
proteins have a decreasing rostrocaudal concentration
gradient in the lumbar CSF.7 Therefore, the volume of
FIG. 1. Assessment of collection gradient in cerebrospinal fluid. Up to 7 portions with 5 ml each of CSF gained by lumbar puncture from 11
subjects (1-11) with Normal Pressure Hydrocephalus were collected and processed as published34 and analyzed with the BioLegend ELISA for total
aSyn to assess possible rostro-caudal gradient (assay: total aSyn from BioLegend)
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CSF taken during an LP can influence the protein con-
centration. To date, 3 studies have addressed a potential
gradient effect on CSF aSyn.
Hong and colleagues analyzed 45 control subjects at
3 different lumbar CSF fractions (<10, 10-15, and 15-
20 mL). This work demonstrated a trend toward
decreased CSF aSyn in late fractions in all cases, after
elimination of samples with elevated hemoglobin lev-
els (indicative of blood contamination, which was
most prevalent in the early fraction).18
In a second study, CSF aSyn showed a slight reduction
from rostral to caudal (thereby suggesting its neuronal
origin) in a small set of gradient samples from patients
with NPH.28 As expected, (blood-derived) total protein
and albumin increased from rostral to caudallumbar
levels. Interestingly, CSF aSyn behaved similarly to
neuron-specific enolase (a neuron-enriched protein that,
similarly to aSyn, is also expressed at high levels in
erythrocytes), whereas the leptomeninges-derived b-
trace protein remained stable, as expected.
A third investigation using the BioLegend ELISA
assay, with 11 NPH subjects and 7 fractions did not
show a gradient effect. To determine the potential effect
of a concentration gradient during the collection of high
volumes of CSF (up to 35 mL), up to 7 separate samples
were prepared per participant over the course of the
tap. CSF aSyn levels were determined in each sample
aliquot. Figure 1 shows the average value normalized to
aliquot 1 of aSyn levels for the 11 participants. The
tight accordance of values in the participants indicates
that CSF levels of aSyn do not significantly vary widely
over the course of sample collection and most impor-
tantly do not increase, which supports that CSF aSyn is
derived from the central nervous system.
Although in these 3 independent studies there was no
significant gradient effect for CSF aSyn, we recommend
the collection of a standarized volume of CSF in all
future studies because other protein biomarkers might
be influenced by the concentration gradient. We there-
fore recommend collecting 10-15 mL, which provides
enough sample volume to compare results between
various patient and control groups and also between
laboratories. Furthermore, CSF should be gently mixed
prior to centrifugation followed by aliquotation. This
will not only help improve the validity of current bio-
markers, but will also facilitate the discovery of novel
CSF biomarkers for which potential gradient effects are
unknown. No correlation between the collected volume
of CSF and the risk of post-LP headache has been
shown.54 For some studies it could therefore be feasible
to collect even larger volumes of samples (eg, for PPMI,
18-mL samples were collected).
Sample Processing for PD Biomarkers
Pipette Tips, Detergent Added to Sample
and Types of Tubes for Aliquoting
It is well known that protein biomarker levels (espe-
cially those with high propensity to aggregate or pre-
cipitate, such as aSyn and Ab 1-42) are influenced by
the type and material of collection/aliquoting tube
used because of nonspecific binding to the tube sur-
face.55-57 Similar findings have been also observed for
aSyn oligomers in the CSF (data not shown).
We compared aSyn levels in the CSF from 9 donors
using siliconized polypropylene, polypropylene, and
polystyrene tubes (Fig. 2). The siliconized polypropylene
tubes show, in some samples, higher levels of aSyn, but
overall in this small sample set the differences were not
significant. Nevertheless, the use of tubes composed of
glass or polystyrene materials with known high protein-
binding capacity58 (not tested here) for the collection
and storage of samples should be avoided.
It has to be noted that the same type of collection
tubes from different vendors may also affect apparent
concentrations of some biomarkers. A comparison
among collection tubes from Bio Plas, Inc. (San Rafael,
CA; 4200SLS, 0.5 mL, screw cap), Eppendorf AG
(Hamburg, Germany; Z666491, 0.5 mL, snap cap),
Fisher Scientific, Inc. (Waltham, MA; 02-681-311,
0.6 mL, snap cap), and Sarstedt AG (N€urnbrecht, Ger-
many; 72.704.600, 0.5 mL, snap cap) revealed variabil-
ity of less than 20% (data not shown). On the other
hand, unpublished preliminary data show for oligomeric
and phosphorylated forms of aSyn (pS129), significant
variability between different sources of polypropylene
tubes (El-Agnaf et al., unpublished data).
There are no studies that directly compare effects of sili-
conized pipette tips. However, adsorption of analytes can
occur within seconds and may differ between CSF and
blood. Because the material of tubes and tips may also
vary between vendors, we recommend selecting one source
for all collection steps and experiments. Storage tubes
should also lock safely (even in the freezer at 2808C) to
avoid evaporation. In addition, treatment of the tube sur-
face (or the sample itself) with Tween-20 reduced Ab4259
and aSyn adsorption (El-Agnaf et al, unpublished data).
FIG. 2. Cerebrospinal fluid aSyn levels in samples (P1-P9) collected at
different temperatures [room temperature (RT), wet ice] and in different
collection tube material (polypropylene, siliconized polypropylene and
styrene) (assay: total aSyn from BioLegend), data shown are mean 6
standard deviation.
a- S Y N U C L E I N B I O M A R K E R S T U D I E S I N P D
Movement Disorders, Vol. 32, No. 8, 2017 1123
We independently investigated the effect of non-ionic
detergents added before analysis on aSyn measurement
from 5 subjects. Thus, CSF aliquots from each of 5 sub-
jects were treated with Tween -20 to 0.1% or 0.05%, NP-
40 to 0.1% or 0.05%, or blank polybutylene succinate
(PBS; Fig. 3). There was a trend toward a decreased detect-
able level of aSyn with Tween 20 having more pronounced
effects than NP-40, but the magnitude of the effect of
detergent varies among individual samples.
Data on collection material and treatment seem
sparse and difficult to interpret or translate into specific
recommendations to make a proper recommendation at
this time. Nevertheless, we advocate collection and ali-
quoting of biological fluids for aSyn measurements
using polypropylene or siliconized tubes. No further
recommendations for the addition of chemicals to the
collection and/or storage of samples can be given at this
point without further investigations.
Centrifugation Condition
Biological fluids should be centrifuged after collection
and before freezing: Even CSF normally contains up to
5 white cells/mL and should therefore be centrifuged
quickly (eg, within 1 hour) before cell lysis occurs.
Additional contamination of cells and extracellular
blood fluid by accidental blood contamination through
LP can be decreased by centrifugation. Centrifugation
speed, time, and temperature are critical variables and
should be standardized within a study. For example,
abundant aSyn protein is found in platelets, which can
be activated by centrifugation at low temperatures.60
Moreover, variable removal of platelets from plasma
could contribute to variability in aSyn plasma measures.
Centrifugation will improve homogeneity of the sam-
ples before analysis.
As centrifugation generates density gradients, we
recommend the transfer of the supernatant to a new
tube that is gently mixed by inverting the tube 3 times
prior to aliquoting the biospecimen.
No recommendations concerning centrifugation
time, speed, or temperature can be given at this time,
as a systematic investigation of their influence on aSyn
levels has not been performed.
Volume of Aliquots
The possible adsorption of protein to surface walls
of storage tubes and evaporation of sample fluid dur-
ing storage led to the investigation of effects of differ-
ent aliquot volumes on aSyn levels.
CSF was obtained from 6 study participants (Fig. 4).
To determine the potential effect of storage aliquot
volume, multiple aliquots were prepared at volumes of
250, 500, and 1000 mL. CSF aSyn levels were deter-
mined in 5 independent aliquots at each volume from
each of the 6 subjects. The results indicated that ali-
quot volume does not affect reproducibility of aSyn
measurement.
Routine Analysis Accompanying Biofluid
Collection for Research Purposes
LPs in symptomatic subjects should also include
analysis of acute/inflammatory processes of the CNS
by analysis of the white and red blood cell counts.
Total protein or albumin should also be measured (eg,
by nephelometry).
The person carrying out the LP should document
any artificial blood contamination or macroscopically
obvious changes from the normal color of CSF.
Red blood cell counts provide the best measure for
evaluating blood contamination (if performed within
30 minutes after lumbar puncture and before lysis of
erythrocytes occurs). Quantification of hemoglobin
might be an alternative to the red blood cell count.
It is optimal for a serum sample to be taken around
the time of CSF collection, and analysis of the serum/
CSF ratios of albumin, immunoglobin G, immunoglo-
bin M, and immunoglobin A is recommended to pro-
vide information on the CSF dynamic, the blood/CSF
FIG. 4. Effect of aliquot volume on aSyn measurements in CSF: CSF
samples from 6 different donors (subject P1-P6) were aliquoted in
250, 500 and 1000 ll (assay: total aSyn from BioLegend). Shown at
right is a bar graph depicting the mean aSyn levels by volume by par-
ticipant. The error bars shown represent one standard deviation.
FIG. 3. Cerebrospinal fluid aSyn levels in samples (P1-P5) collected at
different temperatures [room temperature (RT), wet ice] and in different
collection tube material (polypropylene, siliconized polypropylene and
styrene) (assay: total aSyn from BioLegend), data shown are mean 6
standard deviation.
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barrier, which can alter the CSF proteome, as well as
intrathecal inflammation.
If consent is available, we also recommend freezing
some blood (treated with a nuclease inhibitor such as
ethylenediaminetetraacetic acid) for eventual DNA
analysis.
In addition to autoantibodies and hemoglobin,
elevated levels of other CSF proteins should be con-
sidered as potential modifiers. For example, increased
CSF tau levels have been shown to correlate with
high CSF total aSyn in several independent stud-
ies.30,61,62 CSF tau protein was shown to potentially
influence the clinical associations of CSF total aSyn, for
example, by masking CSF aSyn reduction in PD. It was
suggested that CSF aSyn levels be corrected for CSF tau
protein,61 but we think more research into the mecha-
nism underlying the correlation is needed before such a
recommendation should be made.
Time Delay Between Fluid Collection,
Aliquoting, and Storage
Time delay of processing and storing has been
reported to alter the proteome, especially of serum
and plasma proteins,63,64 but it can also alter the CSF
proteome.65 CSF aSyn levels were reduced after 4 days
of storage at 48C in one study.44
In a second study, the effect of sample handling
delays was evaluated (Fig. 5). CSF was collected from
6 individuals. Samples were kept on ice (28C–88C) or
at ambient conditions for 20 minutes to 48 hours
prior to freezing. Although individual differences oc-
curred, there was no consistent trend for changes of
aSyn levels by storage time and/or temperature.
Storage and Shipment of Samples
for PD Biomarkers
Shipment and Freeze/Thaw Cycles
Freezing biological fluids affects protein stability.66
Freeze-thaw cycles should be avoided for all biological
fluids. A proteomic study found significant alteration
of protein profiles after several freeze/thaw cycles.65
Instability was also reported following dry-ice storage/
shipment and different ways of thawing, because of
acidification and pH shift,67 which need to be taken
into account. For total aSyn, concentrations have been
shown to decrease up to 50% after 6 freeze/thaw
cycles.44 As a consequence, we recommend reporting
the number of freeze/thaw cycles as a confounding
factor or using it as a covariate in the data analysis.
Preanalytical Sample Handling
for PD Biomarkers
Sample Handling Before Analysis
Thawing methods may impact analyses and should
be undertaken carefully and reproducibly. It is impor-
tant that a frozen sample is completely thawed before
utilization.
The effect of thawing methods was evaluated in
4 independent CSF samples using a commercially
available ELISA. Data shown in Figure 6 are the
average1 1 standard deviation for triplicate measure-
ments (3 independent aliquots for each condition). The
magnitude of the effect of thawing methods varied
FIG. 5. Time to freeze: CSF samples from 5 different donors (P1-P5) were held at room temperature (RT, left part) or on 2-8 8C (right part) for 20, 30
minutes, 1, 2, 4, 24 or 48 hours (two replicates each) (one set of samples from a donor with artificial blood contamination was removed) (assay: total
aSyn from BioLegend); data shown are mean 6 standard deviation.
FIG. 6. Different thawing methods were evaluated in 4 independent
CSF samples (P1-P4): data shown are the average +1 Standard devia-
tion for triplicate measurements (3 independent aliquots for each con-
dition). O/N: over night, RT: room temperature (total aSyn ELISA
BioLegend); data shown are mean 6 standard deviation.
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among individual samples. For Ab peptides the trend
was that signal increases with higher temperatures.68
For aSyn, no definite conclusion could be drawn.
Analytical Variables to Consider
for PD Biomarkers
Adding of Blockers for Heterophilic Antibodies
The addition of blockers for heterophilic antibodies
(HAs) to sample diluents in antibody-based assays for
blood biomarkers is recommended. HAs are antibodies
in the sample capable of binding to animal immunoglo-
bulins, and they interfere with the reaction of animal-
derived antibodies that comprise all immunoassays.
HAs generally produce false-positive signals through
cross-binding of capture and reporter antibodies used in
enzyme-linked immunoassays (ELISAs). Recently, it has
been reported that the presence of HAs is a major con-
founder in aSyn ELISAs. HA interference was more
prominent in plasma than the CSF.69 On elimination of
HA interference in the plasma, aSyn levels were signifi-
cantly lower in the PD group than in the control group.
Therefore, decreasing or even eliminating interference
from HAs should always be considered, especially from
blood samples.
aSyn levels in biological fluids depend on the assay
used, as different antibodies bind to different epitopes,
and different calibration standards used affect the lev-
els observed within an assay. The same is also true for
assays measuring the oligomeric and phosphorylated
forms of aSyn. Although the majority of studies have
focused on aSyn phosphorylated at S129, because of
the readily available antibodies, the presence and con-
tribution of other posttranslationally modified forms
of the protein cannot be ruled out and should not be
overlooked.
Because of the abundance of aSyn in peripheral
blood and red blood cells, samples with known acci-
dental blood contamination should be analyzed care-
fully. In one study, the significance level did not
change significantly when comparing the statistics
with and without the samples with known hemoglobin
levels above 200 ng/mL in CSF.25 Nevertheless, the
current recommendation is that samples with known
accidental blood contamination (by erythrocyte count
>50/ml) should be excluded and/or that hemoglobin
should be quantified and samples with levels higher
than 200 ng/mL should be excluded. Further studies
are needed to determine the proper exclusion criteria.
Cutoff points may be different for different assay plat-
forms; more sensitive assays may require lower cutoffs
than others.
CSF flow is known to decrease with age and results
in elevation of total protein in the CSF.7 In addition,
leakage of the blood-CSF barrier becomes more obvi-
ous in older subjects. Therefore, the analysis of the
ratio of aSyn to total protein could be of interest and
should be examined further in future studies.70
With the emergence of assays for aSyn subspecies, it
is recommended to always quantify total aSyn in the
sample and also calculate ratios of the subspecies to
the total aSyn concentration. If a particular aSyn sub-
species is CNS specific, its concentration will not be
influenced by, for example, blood contamination (pro-
vided the contamination is not diluting the CSF
sample).
Calibrator Selection in a-Synuclein
Immunoassays
An immunoassay can be used as an absolute quanti-
tation if a reference material is available and immuno-
assay calibrator values are traceable to this material.71
The current aSyn immunoassays are relative assays
because no reference material is available. Each manu-
facturer uses an internal standard for quantitation of
the calibrators. Consequently, aSyn concentrations in
biological samples will be different when results from
several assays are compared using the same samples.
However, the aSyn assays may be able to quantify the
same protein isoform, resulting in a good correlation
between values generated in the assays with different
antibody pairs or with an orthogonal methodology
(eg, mass spectrometry).72
The selection of the biomaterial for calibration (eg,
native protein, recombinant protein, synthetic peptide,
synthetic/semisynthetic proteins), the matrix in which
calibrators are formulated, and the concentration
range of the calibrators are all driven by the analytical
performance characteristics of immunoassays, includ-
ing parallelism, precision, and the working range of
the assay. For example, the use of synthetic peptides
covering the antibody epitopes of the critical raw
materials is justified if the analytical performance can
be confirmed or if it improves test kit stability com-
pared with the native protein. The integration of an
artificial matrix (eg, PBS containing stabilizers) can
further improve the long-term stability and lot consis-
tency of the kit. The number and level of calibrators,
and the curve fit parameters have a direct impact on the
precision of the assay.73,74 Figure 7a,b shows the com-
parison of 4 calibrators in an immunoassay. Compari-
son of calibrators from different manufacturers, and
with an analytical methodology, will help to better
understand the outcome of published studies.
To compare concentrations across different assays,
different calibrators need to be compared and opti-
mally quantified by an antibody-free reference
method (eg, by mass spectrometry). This work is still
ongoing.
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General Remarks
Because of the multiple potential variations in sample
handling and storage, as well as variables in tissue col-
lection and storage standards at different institutions,
investigators performing analyses with cohorts that have
been collected at different centers must be cautious in
analyzing the results of biomarker studies. We recom-
mend a detailed comparison of the respective standard
operating procedures (SOPs). Ideally, one harmonized
SOP should be used across centers in multicenter stud-
ies. For studies with larger recruitment numbers, we rec-
ommend that multicenter studies use the same SOP. In
addition, a central repository for sample storage (after
freezing at 2808C and a central analysis of marker can-
didates) is recommended to minimize variation.
To compare results from different groups or to
reproduce data and further improve the protocol, it is
important that critical information and parameters
relating to each part of the protocol be documented
and reported.
Given the presence of multiple pathologies in neuro-
degenerative diseases and downstream pathophysiology,
it is unavoidable that investigators will study total aSyn
levels or aSyn isoforms with other markers, such as
Ab42, tau, synaptic proteins, or neuroinflammatory
markers. Optimization of collection and storage proce-
dures for CSF aSyn might not be the optimal protocol
for the other analytes of interest. Investigators will have
to analyze in advance, the perianalytical variables affect-
ing their independent analytes before conducting studies
and, where possible, implementing previously defined
cutoff values for a specific analyte.
Most of the variables discussed here have not been
independently investigated in larger sample sets for
levels of total aSyn. Therefore, a complete and con-
crete set of recommendations cannot be made yet.
However, awareness of the factors that could affect
FIG. 7. Comparison of calibrators: (A) Four independent sources of recombinant aSyn protein (rPeptide, Inc., Bogart USA; Anaspec, Inc., Fremont,
USA; Proteos, Inc., Kalamazoo, USA and UAEU kindly provided by Omar El-Agnaf) were used to generate standard curves in the BioLegend ELISA.
The plots show the raw luminescent counts plotted against the concentration of aSyn protein (ranging from 1500-6.1 pg/mL). (B) ASyn levels were
measured in six CSF samples (QC1-QC6). The value for each sample was obtained by interpolation against standard curves that were generated
using recombinant aSyn protein obtained from four independent sources.
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observed concentration of biomarkers is important for
future research on PD biomarkers (Table 2).
Although we have focused on total aSyn immunoas-
says in this article, we plan to continue to work and
closely coordinate with other research groups that are
pioneering novel mass spectrometry75 and aSyn aggre-
gation-based74,75 methods to enable the development
of accurate assays that allow the quantification of
multiple forms of aSyn in biological fluids.
We anticipate adding regular updates with insights
emerging from further investigations and more precise
recommendations (including perianalytical variables
on the newer assays as mentioned above) and newer
technologies online at www.michaeljfox.org/scientific-
publications.
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